Sandbox/general: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 17: Line 17:
<div class="mw-customtoggle-table14" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table14" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Gram-Positive (Cocco-)Bacilli'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Newborn Conjunctivitis'''
</font>
</div>
 
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
'''Gram-Negative'''
</font>
</font>
</div>
</div>
Line 29: Line 23:
<div class="mw-customtoggle-table15" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table15" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Gram-Negative Cocci in Pairs'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Viral Conjunctivitis'''
</font>
</div>
 
<div class="mw-customtoggle-table16" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Gram-Negative Coccobacilli'''
</font>
</div>
 
<div class="mw-customtoggle-table17" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Gram-Negative Bacilli'''
</font>
</font>
</div>
</div>
Line 86: Line 68:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Gram-Positive (Cocco-)Bacilli}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Newborn Conjunctivitis}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' [[Neisseria gonorrhoeae]] (after 2-5 days)'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 25-50 mg/kg IV x 1 dose (not to exceed 125 mg)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | '''''[[Ampicillin]] 2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Penicillin G]] 4 MU IV q4h'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' [[Chlamydia trachomatis]] (after 3-10 days)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Erythromycin]] base or ethyl succinate syrup 12.5 mg/kg q6h x 14 days'''''<BR> OR <BR> ▸ '''''[[Azithromycin ]] suspension 20 mg/kg po q24h x 3 days'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | '''''[[Gentamicin]] 1.7 mg/kg IV q8h'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''[[Herpes simplex]] (after  2-16 days) †'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Alternative Regimen'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Acyclovir]] 60 mg/kg/day IV divided into 3 daily doses'''''<BR> OR <BR> ▸ '''''[[Trifluridine]] OR [[Vidarabine]] as a topical antiviral therapy'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL><BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''
|† Systemic and CNS disease should be evaluated with PCR of CSF and serum and LFTs in any child with suspected HSV eye infection.
|-
|-
|}
|}
Line 105: Line 89:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Gram-Negative Cocci in Pairs}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Viral Conjunctivitis (pink eye)}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] 4 MU IV q4h'''''<BR> OR <BR> ▸ '''''[[Ampicillin]] 2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 2 g IV q6—8h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table16" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Gram-Negative Coccobacilli}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table17" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Gram-Negative Bacilli}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 2 g IV q6—8h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''<BR> OR <BR> ▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL>
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''No treatment, but if symptomatic, use cold artificial tears'''''
|-
|-
|}
|}
|}
|}
|}
|}

Latest revision as of 20:17, 3 February 2014

▸ Click on the following categories to expand treatment regimens.

Conjunctivitis Medical Therapy

  ▸  Bacterial Conjunctivitis

  ▸  Newborn Conjunctivitis

  ▸  Viral Conjunctivitis

Bacterial Conjunctivitis
Preferred Regimen
Non-gonococcal
Ciprofloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days
OR
Gatifloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days
OR
Levofloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days
OR
Moxifloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days
Gonococcal
Adult dose
Ciprofloxacin 1 gm IM/IV as 1 dose
Pediatric dose
Ciprofloxacin 25-50 mg/kg IV/IM (not to exceed 125 mg) as 1 dose
Alternative Regimen (for non-gonococcal only)
Polymyxin B + Trimethoprim 1–2 gtts q3–6h x 7–10 days
OR
Azithromycin 1%, 1 gtt bid x 2 days, then 1 gtt daily x 5 days
Chlamydia Trachomatis
Preferred Regimen
Azithromycin 1 gm once or twice weekly
Alternative Regimen
Doxycycline 100 mg bid po x 7 days
Newborn Conjunctivitis
Neisseria gonorrhoeae (after 2-5 days)
Ceftriaxone 25-50 mg/kg IV x 1 dose (not to exceed 125 mg)
Chlamydia trachomatis (after 3-10 days)
Erythromycin base or ethyl succinate syrup 12.5 mg/kg q6h x 14 days
OR
Azithromycin suspension 20 mg/kg po q24h x 3 days
Herpes simplex (after 2-16 days) †
Acyclovir 60 mg/kg/day IV divided into 3 daily doses
OR
Trifluridine OR Vidarabine as a topical antiviral therapy
† Systemic and CNS disease should be evaluated with PCR of CSF and serum and LFTs in any child with suspected HSV eye infection.
Viral Conjunctivitis (pink eye)
No treatment, but if symptomatic, use cold artificial tears